Compare DexCom, Inc. (DXCM) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Open Text Corporation — how do they compare? DexCom, Inc. trades at $77.77 (market cap $28.06B), while Open Text Corporation trades at $22.79 (market cap $5.45B). The key difference: DexCom, Inc. is far larger — about 5.1× Open Text Corporation's market cap, and Open Text Corporation pays a 4.84% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | OTEX | |
|---|---|---|
Market Cap | $28.06B | $5.45B |
Sector | Health | Technology |
52-Week High | $89.53 | $39.69 |
52-Week Low | $54.84 | $20.01 |
Enterprise Value | $27.03B | $10.61B |
Dividend Yield | — | 4.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
OpenText (OTEX) trades at $22.76, showing modest daily gains. The stock presents a mixed picture: technical indicators are bearish, but fundamental valuation metrics appear attractive with a P/E of 11.04 and EV/EBITDA of 6.63. The company has consistently beaten earnings expectations in recent quarters and is executing a strategic shift, divesting non-core assets like Vertica while investing in AI and cloud capabilities in Europe. Operating cash flow remains strong at $831M for 2025.
The outlook is cautiously optimistic. The primary opportunity lies in the stock's apparent undervaluation relative to its cash flow and the strategic repositioning towards high-growth AI and cloud segments. Key risks include execution of the new CEO's organic growth plan, competitive pressures in enterprise software, and the stock's current bearish technical momentum which may persist in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
